Hemoccult® ICT
Sell Hemoccult® ICT with Confidence

It’s a Superb Opportunity for Sales Professionals and Excellent Medicine for Physicians and Patients
 

When you represent Hemoccult ICT, you’ll be able to inform your physician clients that it is an immunochemical FOBT (iFOBT) that is clinically proven and backed by a company with 30 years of experience saving lives against colorectal cancer.1,2
   

Key Points to Remember:
 
1. The Hemoccult ICT Opportunity

Sell to your existing customer base

Increase your revenue and profit dollars

Quadruple the revenue vs. guaiac-based FOBTs

Present the best screening method available with confidence

Backed by the Hemoccult brand name and reputation

Proven clinically effective


2. Immunochemical vs. Guaiac FOBTs

As an immunochemical FOBT (iFOBT), Hemoccult ICT has major advantages over traditional guaiac FOBTs:

Immunochemical Advantage
Result
No diet or drug restrictions

 Better patient compliance
Increased specificity with high sensitivity

 Better than a guaiac FOBT
Specific to GI bleeding

 Ideal CRC screening product
New CPT Codes=G0328QW, 82274QW*
 Higher reimbursement of
$22.22 for 2005*
No drug interferences Fewer false-positive and negatives

3. Hemoccult ICT is Better for Your Physician Clients

Better health care

No diet or medication restrictions

Improved patient compliance

Fewer false positives

Favorable reimbursement
Test Type
Reimbursement
Guaiac FOBT $4.54 *
iFOBT $22.22*

4. Hemoccult ICT Benefits for Patients

Patient friendly

Easy-to-follow collection instructions

No diet or drug restrictions

Safe, non-invasive

Similar sample collection technique

Fewer false positives
   

References:

1. Data on file, Beckman Coulter, Inc Hemoccult ICT Product Instructions 2005.

2. Mandel, Jack S., et al.: “The effect of fecal occult-blood screening on the incidence of colorectal cancer,” NEJM 2000; 343: 1603-1607.

*Exemplar CPT and reimbursement provided. Refer to regional CMS fee schedule for relevant/current CPT codes & reimbursement.